(ANGO) AngioDynamics, Inc. Porters Five Forces Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ANGO) AngioDynamics, Inc. Complete Analysis Pack
Elevate Your Analysis with the Complete Porter's Five Forces Analysis
This AngioDynamics, Inc. Porter's Five Forces Analysis helps you understand the competitive forces shaping the company’s industry and profitability. The page already shows a real sample of the actual report, so you can review the content before buying. Purchase the full version to get the complete ready-to-use analysis.
Suppliers Bargaining Power
Qualified medical-grade inputs
AngioDynamics’s FY2025 net sales were about $300 million, so small shifts in input cost can still move margins. Its catheters, ports, guidewires, and ablation tools need sterile, traceable, medical-grade parts, and only a narrow set of approved vendors can meet those standards. That gives suppliers leverage on price, lead times, and contract terms.
Regulatory compliance burden
Regulatory compliance raises supplier power for AngioDynamics, Inc. because inputs for regulated devices must pass strict validation and documentation, so the approved supplier pool stays small. In fiscal 2025, AngioDynamics generated about $300 million in sales, but even one component change can trigger new qualification work and revalidation costs. That makes substitution slow and gives key suppliers more leverage when production needs to change.
Single-source exposure
AngioDynamics, Inc. faces single-source exposure because some parts, subassemblies, and proprietary materials can come from limited suppliers, so any delay can stop production and cut product availability. With annual net sales around $300 million in FY2025, even a short supply break can hit revenue and margins fast. That raises supplier power, especially where surgeons face high switching costs and need validated devices.
Manufacturing outsourcing dependence
AngioDynamics' outsourced manufacturing and sterilization steps give contract partners pricing power, because any capacity squeeze in medtech can raise input costs and extend lead times. That can pressure margins and service levels if a key vendor tightens terms.
So, supplier power is moderate to high when switching is slow or validation is costly. AngioDynamics has to manage dual sourcing, inventory, and partner performance closely to protect availability and gross margin.
- Outsourced steps can raise pricing power.
- Capacity limits can tighten terms.
- Validation slows fast supplier switching.
- Careful partner control protects margins.
Scale offsets some pressure
AngioDynamics, Inc.'s broad portfolio and steady reorder needs give it more leverage than small niche peers, so suppliers face a larger, more stable buyer. Multi-year sourcing ties also help smooth price swings and reduce switching risk. That keeps supplier power moderate, not extreme.
- Broad product mix supports buying leverage.
- Recurring volumes aid term negotiations.
- Long sourcing ties cut volatility.
- Supplier power stays moderate overall.
AngioDynamics Faces Moderate-High Supplier Power on Tight Vendor Access
AngioDynamics, Inc. has moderate-to-high supplier power because FY2025 net sales were about $300 million, while sterile, validated medical inputs come from a narrow vendor pool. Single-source parts, outsourcing, and revalidation costs make switching slow, so key suppliers can push on price, lead times, and terms.
| Key factor | FY2025 signal |
|---|---|
| Net sales | About $300 million |
| Approved vendors | Narrow pool |
| Switching cost | High |
| Supplier power | Moderate to high |
What is included in the product
Detailed Word Document
Assesses AngioDynamics, Inc.'s competitive pressures, supplier and buyer power, and threats from entrants and substitutes.
Customizable Excel Spreadsheet
A quick five-forces snapshot that cuts through market complexity and highlights AngioDynamics’ key pressures fast.
Reference Sources
Helps validate AngioDynamics assumptions fast with traceable, credible sources that strengthen diligence and decision-making.
Customers Bargaining Power
Hospital purchasing concentration
AngioDynamics sells into a market where hospitals, health systems, and GPOs centralize buying, so one deal can cover many sites at once. That scale lets buyers push hard on price, terms, and service, and it raises switching pressure on suppliers. With a few large GPOs shaping much of U.S. hospital procurement, customer bargaining power stays high.
Clinical committee review
Clinical committee review is a real gatekeeper: in large health systems, value analysis committees and formulary-style reviews can delay AngioDynamics products until teams see proof on outcomes and total cost of care. In FY2025, AngioDynamics reported about $304 million in net sales, so even small approval delays can matter. Buyers can also push for price cuts, pilots, or contract concessions before adoption.
Reimbursement pressure
Hospitals and physicians still work under tight payer and government rates; Medicare covered about 66 million people in 2025, so reimbursement stays a big gatekeeper. CMS set the 2025 physician fee schedule conversion factor at $32.35, down 2.8%, which makes buyers more price sensitive. For AngioDynamics, that means customers favor devices that cut procedure time and support clear utilization, then push harder for discounts when payment tightens.
Switching is possible in many categories
AngioDynamics, Inc. faces strong buyer leverage because many products sit in mature, commoditized categories where functionally similar devices from larger rivals are easy to compare. If clinical outcomes are close, switching costs stay low, so hospitals can move orders with limited disruption and push on price. In fiscal 2025, that pressure mattered more as smaller suppliers had less scale than major medtech peers.
- Low switching costs raise buyer power.
- Comparable outcomes weaken pricing power.
- Mature lines face the most pressure.
Specialty relationships reduce pressure
In advanced ablation and complex vascular access, clinicians often stick with tools they know, so training, procedural support, and repeat use can soften price pressure. That said, AngioDynamics still faces moderate to high customer power because hospitals and group buyers can compare options and push on price and terms.
Strong clinical results help, but they do not fully offset buyer leverage in a market where purchasing teams often control access. AngioDynamics' protection comes more from workflow trust than from pricing power.
- Training and support lower switching risk.
- Clinical familiarity reduces price sensitivity.
- Buyer power stays moderate to high.
- Trust helps more than list price.
AngioDynamics Faces Strong Buyer Pressure
AngioDynamics faces high customer bargaining power because hospitals, health systems, and GPOs buy in bulk and can switch among similar devices with limited friction. FY2025 net sales were about $304 million, so even small pricing or approval delays can hit revenue. CMS cut the 2025 physician fee schedule conversion factor to $32.35, which keeps buyers price-focused. Clinical proof helps, but it only partly offsets buyer leverage.
| Driver | Signal |
|---|---|
| FY2025 net sales | About $304 million |
| CMS 2025 fee factor | $32.35, down 2.8% |
| Buyer structure | Hospitals and GPOs |
Preview Before You Purchase
AngioDynamics, Inc. Porter's Five Forces Analysis
This preview shows the exact AngioDynamics, Inc. Porter's Five Forces Analysis you'll receive after purchase—no mockups, no placeholders.
What you see here is the same professionally written document, fully formatted and ready to use right away.
Once you buy, you’ll get instant access to this exact file.
Rivalry Among Competitors
Large medtech competitors
AngioDynamics faces large medtech rivals like Medtronic, Boston Scientific, and Becton Dickinson, each with FY2025 sales in the billions and far bigger sales teams, R and D budgets, and hospital contracts. Their scale lets them bundle catheters, implants, and guidewires, then push pricing across lines. That keeps rivalry intense in vascular access and interventional devices, where AngioDynamics lacks similar breadth.
Fast product innovation cycle
Clinical teams want better efficacy, easier use, and smoother workflow, so AngioDynamics, Inc. faces sharp rivalry in fast-moving niches. In FY2025, the Company kept spending on R&D and evidence work while competitors with faster launches can grab share quickly in small segments. That makes product speed and clinical proof just as important as price.
Fragmented niche competition
AngioDynamics competed in FY2025 with about $290 million in net sales across 3 core areas: ablation, endovascular therapy, and access. Each niche has specialist rivals, so no single company owns the whole field, but the combined pressure stays high. That makes rivalry broad and persistent across the full portfolio.
Pricing and contract battles
Hospitals often award AngioDynamics, Inc. business through competitive bids and multi-year contracts, so price cuts can decide wins as much as product fit. Vendors also bundle service, training, and financing, which keeps pressure on margins. In this kind of market, even small discounting can erode profitability fast.
Bid-driven sales increase price pressure.
Multi-year deals raise switching costs.
Bundling can beat product features.
Discounts can squeeze margins.
International and channel competition
International and channel competition is high because AngioDynamics, Inc. faces not just global device groups but also local makers that can win share through regional distributors. The company reported net sales of $298.0 million in FY2024, and its smaller scale can make market access and distributor ties more fragile than larger rivals. Regulatory clearance and local pricing can shift share fast.
- Global and local rivals both pressure share
- Distributor access can move wins quickly
- Regulatory timing changes competitive position
This raises rivalry because competitors can attack in direct sales and through indirect channels at the same time.
AngioDynamics Faces Fierce Rival Pressure in FY2025
Competitive rivalry is high for AngioDynamics, Inc. in FY2025 because larger medtech rivals like Medtronic and Boston Scientific can bundle products, outspend on R and D, and win hospital contracts. With about $290 million in net sales, AngioDynamics, Inc. competes in narrow niches where clinical proof, speed, and price all matter.
| Metric | FY2025 |
|---|---|
| AngioDynamics, Inc. net sales | About $290 million |
| Core segments | 3 |
| Rival scale | Billions in sales |
Substitutes Threaten
Open surgery alternatives
Open surgery still competes with AngioDynamics in some oncology, vascular, and drainage cases, especially when a surgeon needs direct access or expects complex anatomy. These older methods are less minimally invasive, but they remain credible fallback options, so substitution risk stays real in selected procedures. In practice, that can pressure AngioDynamics’ device mix and pricing, especially where outcomes or case costs do not clearly justify the switch.
Alternative ablation technologies
NanoKnife and Solero face at least 4 common substitutes—radiofrequency, microwave, cryoablation, and other energy platforms—so physicians can switch when lesion type, workflow, or hospital preference points elsewhere. In oncology ablation, that keeps substitution pressure moderate to high, because many centers already standardize on familiar systems with shorter setup and broad clinical use.
Drug therapy and watchful management
Drug therapy and watchful management can delay or replace device use when disease advances slowly, so AngioDynamics, Inc. faces substitute pressure in some vascular and oncology cases. That matters because clinicians may prefer meds, imaging, and monitoring over an immediate procedure, which can shrink near-term demand for catheters, ablation, and access products. The threat is strongest where symptoms are mild and intervention can wait.
Alternative access routes
AngioDynamics’ vascular access tools face strong substitute pressure from peripheral IVs, standard central lines, and other catheter setups. In short-duration therapy, care teams often pick the simplest option that meets the need, so a lower-cost PIV can win the case. That makes substitution risk highest when treatment lasts only hours to a few days.
- Peripheral IVs are the easiest substitute.
- Central lines fit broader therapy needs.
- Short therapies favor simple devices.
Procedure redesign by clinicians
Procedure redesign by clinicians keeps substitution risk real for AngioDynamics, Inc. Hospitals can shift pathways to use fewer branded devices when better imaging, new workflows, or alternate surgical techniques cut device need. That means even differentiated products can lose share if clinicians redesign care around lower-cost or less device-heavy steps.
- Care pathways can replace device use
- Imaging upgrades can reduce demand
- Workflow changes can lower usage
- Substitution risk stays meaningful
AngioDynamics Faces Moderate-to-High Substitution Pressure
Threat of substitutes for AngioDynamics, Inc. is moderate to high because physicians can switch to open surgery, drug therapy, or rival energy systems when anatomy, workflow, or cost favors them. In vascular access, peripheral IVs and standard central lines often win for short therapy. Care-path redesign can also cut device use.
| Area | Main substitutes | Pressure |
|---|---|---|
| Oncology | RFA, microwave, cryoablation | High |
| Vascular access | PIVs, central lines | High |
Entrants Threaten
Heavy regulatory barriers
Heavy regulatory barriers keep new rivals out of AngioDynamics, Inc.'s market. A device maker must clear FDA review, build quality systems, prove clinical value, and keep up post-market reporting, which can take months to years and burn cash fast. Because these steps are costly and slow, regulation is one of the biggest entry barriers in medical devices.
Trust and clinical evidence requirements
Hospitals and physicians buy on trust, so they favor devices with proven safety, training support, and published outcomes. New entrants often lack the clinical evidence, and that slows adoption in a market where U.S. hospital spending on medical and surgical supplies topped $100 billion in 2025. That evidence gap helps AngioDynamics keep entry barriers high.
Capital intensive manufacturing
Precision manufacturing, sterilization, testing, and sterile inventory controls can require millions of dollars in upfront spending, so AngioDynamics, Inc. faces a high entry barrier. Startups also struggle to build reliable supply chains for sterile devices, where one failed validation or recall can wipe out early cash. That cost and execution risk make new entrants less likely and slower to scale.
Sales channel access is hard
Sales channel access is a real barrier for AngioDynamics, Inc. New entrants must win GPO and hospital system contracts, and those deals usually favor vendors with a proven track record. They also need a clinical sales force and procedure support, which raises cost and slows launch. That makes rapid entry unlikely.
- GPOs reward trust and scale.
- Clinical support takes time to build.
- Reputation blocks fast switching.
Niche innovation can still enter
Broad entry is hard, but AngioDynamics, Inc. still faces niche startup risk: a single new catheter, ablation, or vascular-access idea can win a narrow clinical lane. Venture capital and university tech transfer can move these ideas fast, so the threat is low to moderate overall, but moderate in adjacent niches.
- Niche tech can bypass broad scale barriers.
- VC and lab spinouts speed entry.
- Risk stays low to moderate overall.
AngioDynamics Faces Low Entry Threat as Barriers Keep New Rivals Out
Threat of new entrants for AngioDynamics, Inc. is low because FDA clearance, clinical proof, sterile manufacturing, and GPO access all demand time and capital. In 2025, U.S. hospital spending on medical and surgical supplies topped $100 billion, but that scale still favors incumbents with trust and contracts. New rivals can still enter narrow niches, so the risk stays low to moderate.
| Barrier | Why it matters |
|---|---|
| FDA and quality systems | Slow and costly entry |
| Clinical evidence | Hospitals prefer proven devices |
| Manufacturing and supply | High setup and recall risk |
| GPO access | Contracts favor incumbents |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.